Anti-hyperlipedemic activity of Panchavalkala Ghana Vati
Phase 2
- Conditions
- Health Condition 1: E785- Hyperlipidemia, unspecified
- Registration Number
- CTRI/2023/10/058952
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients who are confirmed to have increased levels of Cholesterol, Triglycerides and LDL with the help of a Lipid Profile Test.
Exclusion Criteria
1. Patients who are K/C/O DM and HTN not under control
2. Immunocompromised patients
3. Patients with severe systemic illness.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To look for decrease in the levels of Cholesterol, Triglycerides and LDL through Lipid Profile TestTimepoint: Before Treatment and After Treatment (After 1 month)
- Secondary Outcome Measures
Name Time Method ab Values of Lipid Profile TestTimepoint: After 1 month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Panchavalkala Ghana Vati's anti-hyperlipidemic effects in phase II trials?
How does Panchavalkala's lipid-lowering efficacy compare to statins or PCSK9 inhibitors in hyperlipidemia management?
Which biomarkers correlate with response to Panchavalkala's lekhana karma in E785 hyperlipidemia subtypes?
What adverse events are reported in Ayurvedic anti-hyperlipidemic trials like CTRI/2023/10/058952 and their management?
Are there synergistic combination therapies involving Panchavalkala and synthetic lipid-lowering agents for metabolic disorders?